We came across a bullish thesis on Merck & Co., Inc. (MRK) on Substack by Investing Intel. In this article, we will summarize the bulls’ thesis on MRK. Merck & Co., Inc. (MRK)’s share was trading at ...

AstraZeneca has licensed in an antisense drug from Ionis Pharmaceuticals to treat kidney disease in a deal worth up to $330 million. Antisense drugs contain non-coding strands of mRNA that block ...

Only last month, the US company Merck agreed to pay a potential $1.4 billion to partner on an immuno-oncology asset with Chinese firm, Sichuan Kelun Pharmaceutical. Merck is not alone, with a ...

CR Longdation, a subsidiary of China's China Resources Holdings Co., has sent an offer to Hong Kong-based New World Development Co. regarding the acquisition of the K11 Art Mall in the Hong Kong ...